---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-26-022876"
form_type: "8-K"
ticker: "VXRT"
cik: "0000072444"
company_name: "Vaxart, Inc."
filed_at: "2026-07-07T12:00:09+00:00"
generated_at: "2026-07-07T12:05:15.548163+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Vaxart reports positive 12-month safety data from Phase 2b sentinel cohort of oral COVID-19 vaccine

## Summary
- No vaccine-related SAEs or sustained Grade 3+ AEs in either arm (201 oral pill, 199 mRNA).
- Most common AEs for oral pill: malaise/fatigue (20.9%), headache (18.9%), anorexia (10.0%).
- Sentinel cohort not powered for efficacy; 33 symptomatic COVID cases in oral arm vs 30 in mRNA arm.
- Complete study data (~5,000 main cohort participants) anticipated in 2027.
- Project NextGen/BARDA award valued at up to $344.8 million supports the trial.

## SEC filing metadata
- accession: 0001437749-26-022876
- form_type: 8-K
- ticker: VXRT
- cik: 0000072444
- company_name: Vaxart, Inc.
- filed_at: 2026-07-07T12:00:09+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/72444/000143774926022876/0001437749-26-022876-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/72444/000143774926022876/vxrt20260706_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-26-022876
- JSON: https://secwatch.observer/filing/0001437749-26-022876.json
- Plain text: https://secwatch.observer/filing/0001437749-26-022876.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.